Price$6.25-0.43 (-6.43%)
2026-07-162026-10-16
News · 26 weeks340%
2026-04-192026-10-11
Mix1190d
- SEC Filings4(36%)
- Insider3(27%)
- Other2(18%)
- Earnings2(18%)
Latest news
25 items- PRInogen to Report Third Quarter 2026 Financial Results on November 5, 2026Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. On the same day, the Company will host a conference call at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.Individuals interested in listening to the conference call may do so by dialing:U.S. domestic callers (877) 841-3961Non-U.S. callers (201) 689-8589Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page o
- SECInogen Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Inogen Inc (0001294133) (Filer)
- PRInogen Announces Divestiture of Its U.S. Oxygen Rental Business to RotechTransaction advances Inogen’s strategic shift toward a more streamlined commercial model supporting higher revenue growth and adjusted operating incomeInogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has signed a definitive agreement to divest its U.S. oxygen rental business to Rotech Healthcare, a leading national provider of home respiratory and medical equipment. Under the agreement, Rotech will acquire specified rental assets for a total estimated cash consideration of up to $25 million. The transaction is expected to close in the fourth quarter of 2026, subject to customary closing
- INSIDERSEC Form 4 filed by Inogen Inc4 - Inogen Inc (0001294133) (Issuer)
- INSIDEREVP, Bus Dev, GC & Sec Smith Kevin P. was granted 1,500 shares, converted options into 18,136 shares and covered exercise/tax liability with 8,671 shares, increasing direct ownership by 50% to 32,972 units (SEC Form 4) (for tax liability)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERCEO and President Smith Kevin Raymond Merrill was granted 1,500 shares, increasing direct ownership by 1% to 134,962 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- SECSEC Form 10-Q filed by Inogen Inc10-Q - Inogen Inc (0001294133) (Filer)
- SECInogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inogen Inc (0001294133) (Filer)
- PRInogen Announces Second Quarter 2026 Financial ResultsReported second quarter revenue of $95.1 million Company raises full-year adjusted EBITDA guidance to approximately $4.0 million Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2026. "Our second quarter results demonstrate continued demand for our products and validate the progress of our strategy to expand and diversify Inogen’s respiratory care portfolio," said Kevin Smith, President and Chief Executive Officer. "We are building momentum through new product launches, gaining traction in key markets, and driving greater operating leverag
- PRSmartbird Nominates Tech Industry Veterans Elizabeth Mora and Dan Kasun for Election to Its Board of DirectorsSAN FRANCISCO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Smartbird, Inc. (NASDAQ:BIRD), an AI infrastructure provider, today announced the nomination of Elizabeth Mora and Dan Kasun for election to its board of directors at the company’s next annual meeting of stockholders. Mora is an experienced board director and finance executive with a strong governance background. She previously served as chief financial officer of Draper Laboratory and Harvard University and is currently chair of the board of directors of Inogen Inc. (NASDAQ:INGN), serves on the board of directors of semiconductor and laser equipment company MKS Instruments (NASDAQ:MKSI) where she chairs the audit committee, and serves on t
- SECSEC Form S-8 filed by Inogen IncS-8 - Inogen Inc (0001294133) (Filer)
- PRInogen to Report Second Quarter 2026 Financial Results on August 6, 2026Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2026 financial results after the market closes on Thursday, August 6, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.Individuals interested in listening to the conference call may do so by dialing:U.S. domestic callers (877) 841-3961Non-U.S. callers (201) 689-8589Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investor
- INSIDERSEC Form 4 filed by EVP, COO Reding Andrew P.4 - Inogen Inc (0001294133) (Issuer)
- INSIDERSEC Form 3 filed by new insider Reding Andrew P.3 - Inogen Inc (0001294133) (Issuer)
- INSIDEREVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold $72,146 worth of shares (10,938 units at $6.60) as part of a pre-agreed trading plan, decreasing direct ownership by 68% to 5,039 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- SECInogen Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Inogen Inc (0001294133) (Filer)
- PRInogen Announces the Appointment of Andy Reding as Chief Operating OfficerNewly created role strengthens leadership structure to support Inogen’s global commercial and operational execution Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Andy Reding to the newly created role of Chief Operating Officer, effective Monday, July 6, 2026. Mr. Reding will be responsible for driving revenue and operational performance, aligning cross-functional priorities, and helping ensure Inogen’s strategy is translated into efficient and measurable outcomes. "As we continue to diversify Inogen’s business through new product launches and geographic expansion, we
- SECSEC Form S-8 filed by Inogen IncS-8 - Inogen Inc (0001294133) (Filer)
- INSIDERDirector Sahney Mira Kirti was granted 28,081 shares, increasing direct ownership by 71% to 67,805 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Jamali Vafa was granted 28,081 shares, increasing direct ownership by 187% to 43,081 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Boehnlein Glenn S was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Rider Heather D. was granted 28,081 shares, increasing direct ownership by 32% to 116,282 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Mora Elizabeth was granted 28,081 shares, increasing direct ownership by 35% to 107,261 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Ladone Mary Kay was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector King Kevin M was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
INGN FAQ
7 questionsWhat does Inogen Inc do?
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as...Where does INGN stock trade?
Inogen Inc (INGN) is listed on NASDAQ.What sector and industry is INGN in?
Inogen Inc operates in the Health Care sector, Industrial Specialties industry.When did Inogen Inc go public?
Inogen Inc (INGN) completed its IPO in 2014.What are analysts saying about INGN?
Inogen Inc has had 8 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $1400.00 price target on 2025-06-16.What companies are similar to INGN?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare INGN side-by-side with any of them on Quantisnow.How can I track INGN on Quantisnow?
Quantisnow aggregates Inogen Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INGN to receive live email and push alerts on every new disclosure.